• linkedin
  • Increase Font
  • Sharebar

    Kidney Ca: Cytoreductive nephrectomy appears to be protective

    • In a group of 606 propensity-matched metastatic renal cancer patients from the Surveillance, Epidemiology, and End Results database, upfront cytoreductive nephrectomy had a 20-month median survival compared to only 8 months without surgery (hazard ratio=0.57).
    • Researchers evaluating treatment of small renal masses found a local recurrence rate of less than 1% for surgery and nearly 11% for percutaneous ablation.
    • In mice, simultaneous laser thermal ablation and injection of sorafenib (Nexavar)-coated nanorods led to synergistic killing, with 100% absence of viable cells on subsequent inspection compared to 62% with laser thermal ablation alone.
    • Follow-up of a large multinational trial of systemic everolimus (Afinitor) versus placebo for renal angiomyolipoma confirmed early findings of safety and efficacy. One hundred and twelve patients followed for more than 4 years had sustained reduction in tumor volume and no episodes of bleeding.
    • Researchers presented a preoperative assessment model for metastatic renal cancer based on 313 cytoreductive nephrectomies performed between 1990 and 2010. Using a simple score model, they demonstrated that with a score of 0 points, cancer-specific survival at 1 year was 81% relative to only 30% for 10 points or more.
    • Reduction of renal function due to surgery does not confer the same overall survival disadvantage as pre-existing medical renal dysfunction.

    Next: Effect of perioperative transfusions on 5-year recurrence free, overall survival survival

    Benjamin P. Saylor
    Saylor is content managing editor for Urology Times.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available